



Headquarters

Thousand Oaks, California

Staff

Approximately
28,000 worldwide

Stock Listing

NASDAQ: AMGN

Chairman and CEO

Robert A. Bradway

2024 Financial Highlights

Total revenue

\$33.4 billion

Product sales

\$32 billion

R&D expense

\$6.0 billion

Address/Phone

One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Main

805.447.1000

Investors

805.447.1060

About Amgen

Our Mission: To Serve Patients

Amgen harnesses the best of biology and technology to fight the world's toughest diseases, and make people's lives easier, fuller and longer.

We helped establish the biotechnology industry more than 40 years ago. Our investment in research and development has a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, inflammatory diseases and rare diseases.

Amgen is part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

Products

ACTIMMUNE® (Interferon gamma-1b)

Aimovig® (erenumab-aooe)

AMJEVITA® (adalimumab-atto)

Aranesp® (darbepoetin alfa)

AVSOLA® (infliximab-axxq)

BKEMV™ (eculizumab-aeeb)

BLINCYTO® (blinatumomab)

BUPHENYL® (sodium phenylbutyrate)

Enbrel® (etanercept)

EPOGEN® (epoetin alfa)

EVENITY® (romosozumab-aqqg)

IMDELLTRA® (tarlatamab-dlle)

IMLYGIC® (talimogene
laherparepvec)

KANJINTI® (trastuzumab-anns)

KRYSTEXXA® (pegloticase)

KYPROLIS® (carfilzomib)

LUMAKRAS® (sotorasib)

MVASI® (bevacizumab-awwb)

Neulasta® (pegfilgrastim)

NEUPOGEN® (filgrastim)

Nplate® (romiplostim)

Otezla® (apremilast)

Parsabiv® (etelcalcetide)

Pavblu™ (afibercept-ayyh)

PROCYSBI® (cysteamine bitartrate)

Prolia® (denosumab)

RAVICTI® (glycerol phenylbutyrate)

Repatha® (evolocumab)

RIABNI® (rituximab-arrx)

TAVNEOS® (avacopan)

TEPEZZA® (teprotumumab-trbw)

TEZSPIRE® (tezepelumab-ekko)

UPLIZNA® (inebilizumab-cdon)

Vectibix® (panitumumab)

WEZLANA™ (ustekinumab-auub)

XGEVA® (denosumab)

Aimovig® is developed in collaboration with Novartis. For information about our pipeline and therapies, visit www.amgen.com.

REACHING SERIOUSLY ILL PATIENTS WORLDWIDE

We have a presence in approximately 100 countries and regions worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on four therapeutic areas: general medicine, rare disease, inflammation and oncology, delivering innovative medicines to help people live longer, fuller, happier lives.

ACCELERATING THERAPIES FOR PATIENTS WITH CUTTING-EDGE SCIENCE

We combine our understanding of human genetics and disease biology with advanced science and technologies, like protein engineering and AI capabilities, to identify and deliver the most effective treatments for people living with some of the world's toughest diseases.

MAKING MEDICINES SAFELY AND RELIABLY

Many of Amgen's medicines are made through a highly complex process involving living cells. We're committed to delivering for "every patient, every time," and we have a long-running reputation for the reliability of our supply chain.

OPERATING RESPONSIBLY

Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines. We also help build a better world by focusing on corporate sustainability issues that matter most to our business and our stakeholders.

THE AMGEN FOUNDATION

The Amgen Foundation is inspiring the next generation of scientists and future problem solvers, providing best-in-class science education at no cost to students through its signature programs, including LabXchange, Amgen Scholars, and the Amgen Biotech Experience. To date, the Foundation has donated more than \$475 million to local, regional, and international non-profits that impact society in inspiring and innovative ways.

Investor Information: This fact sheet is a summary of more detailed disclosure that can be found in Amgen's filings with the U.S. Securities and Exchange Commission and its press releases. This fact sheet contains forward-looking statements that involve significant risks and uncertainties, discussion of which can be found in Amgen's most recent Forms 10-K, 10-Q, and 8-K and on <http://investors.amgen.com>. The information in this fact sheet is given as of the date below, and Amgen does not undertake any obligation to update any information in this document.

